

Title:

Severe cirrhosis is associated with increased surgical mortality and morbidities in patients with hip fractures: a propensity-score matched analysis using a large inpatient database

Short running head: Cirrhotic Patients with Hip Fracture

Authors:

Osamu Hamada, MD,*† Jung-ho Shin, DrPH,† Takahiko Tsutsumi, MD,*† Ayako Tsunemitsu, MD,*† Noriko Sasaki, PhD,† Susumu Kunisawa, PhD,† Kiyohide Fushimi, PhD,‡ Yuichi Imanaka, PhD†

From the *Department of General Internal Medicine, Takatsuki General Hospital, Takatsuki, Osaka; †Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto; ‡Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Bunkyo-ku, Tokyo.

Author Contributions:

Osamu Hamada: Conceptualization, Methodology, Formal analysis, Data Curation, Writing-Original draft; Jung-ho Shin: Conceptualization, Methodology, Formal analysis, Data Curation, Writing-Reviewing and Editing; Takahiko Tsutsumi: Writing-Reviewing and Editing; Ayako Tsunemitsu: Writing-Reviewing and Editing; Noriko Sasaki: Conceptualization, Methodology, Writing-Reviewing and Editing; Susumu Kunisawa: Resources, Writing-Reviewing and Editing; Kiyohide Fushimi: Resources, Writing-Reviewing and Editing; Yuichi Imanaka: Conceptualization, Methodology, Formal analysis, Writing-Reviewing and Editing, Supervision, Funding acquisition.

Yuichi Imanaka has received research funding from JSPS KAKENHI Grant Number JP19H01075, ISHIZUE 2022 of Kyoto University, and MHLW Grant Numbers JPMH22AA2003 and JPMH21IA1005.

All authors have no potential conflicts of interest to disclose.

Corresponding author: Yuichi Imanaka, PhD

Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto.

Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

Tel: +81-75-753-4454, Fax: +81-75-753-4455

E-mail: imanaka-y@umin.net

Mini-abstract:

We conducted propensity-score matched analysis to examine mortality of groups of patients with hip fractures in a national patient database according to degree of severity of cirrhosis. Patients with higher Child-Pugh class of cirrhosis was shown to be associated with higher mortality.

Abstract

Objective: The aim of this study was to compare postoperative mortality and morbidities in patients with hip fractures undergoing surgery by Child-Pugh classes.

Summary Background Data: Advanced cirrhosis is associated with increased mortality in several types of surgery, but the impact of severity of cirrhosis on postoperative outcomes in patients with hip fractures remain unclear.

Methods: We analyzed data of patients with hip fracture within a large inpatient database. We performed three sets of 1:1 propensity-score matching for four groups: cases without cirrhosis, and Child-Pugh classes A, B and C. We compared in-hospital mortality, length of stay, hospitalization fee, rate of 30-day readmission and complications in the following three pairs: cases without cirrhosis vs Child-Pugh class A, Child-Pugh class A vs B, and Child-Pugh class B vs C.

Results: Among 833,648 eligible cases, propensity-score matching created 1,065 pairs between cases without cirrhosis vs Child-Pugh class A, 1,012 pairs between Child-Pugh class A vs B, and 489 pairs between Child-Pugh class B vs C. In-hospital mortality did not differ between cases with cirrhosis and those with Child-Pugh A classification (1.69% vs 1.41%; RD -0.28%; 95% CI: -1.34%–0.78%). In-hospital mortality was significantly higher in patients with Child-Pugh B classification than in those with A classification (1.48% vs 5.93%; RD 4.45%; 95% CI: 2.79%–6.10%), and in those with Child-Pugh C classification compared with those with B classification (6.34% vs 28.43%; RD 22.09%; 95% CI: 17.54%–26.63%). Among cases with cirrhosis, those in more severe Child-Pugh classes had longer length of stay, higher hospitalization fees and higher ratio of complications, such as acute liver failure, upper gastrointestinal bleeding and sepsis.

Conclusions: Our results could help to identify patients at high-risk of postoperative mortality and morbidity among those with both hip fracture and cirrhosis. Patients with Child-Pugh C classification may benefit from discussions about nonsurgical management, goals of care, and overall prognosis.

Introduction:

The heavy burden of cirrhosis was shown in recent global epidemiological data.¹ Patients with cirrhosis are living longer with more advanced disease because of improved medical and surgical management.² As a result, they are at risk for hip fractures as well as other diseases and morbidities that were not previously a problem for patients with cirrhosis.³ Despite advances in modern surgical and intensive care treatment, perioperative mortality remains high in patients with cirrhosis that undergo surgery.⁴ Prognostic scoring systems for the underlying surgical disease in combination with the state of liver disease have therefore been investigated.⁵ Scoring systems for cirrhosis, such as Child-Pugh classification and model for end-stage liver disease (MELD), have been correlated with outcome.⁶⁻⁸ A recent review summarized 87 studies that used Child-Pugh classification or MELD. It suggested the safety of surgery for patients with Child-Pugh A classification, which had mortality <5–10% in patients undergoing non-hepatic abdominal surgery compared with 10–40% for Child-Pugh B classification and 20–100% for Child-Pugh C classification.⁹ In another study, cardiac surgery was reportedly appropriate for patients with Child-Pugh A classification and selected patients with Child-Pugh B classification, although there was a 67% risk of in-hospital mortality for patients with Child-Pugh C classification.¹⁰

The number of patients with hip fractures undergoing surgery increases along with a large increase in the elderly population worldwide, because the rate of hip fracture increases exponentially with age.¹¹ Hip fractures greatly reduce a patient's quality of life and physical function, and they are associated with serious mortality in the first year after injury.¹²⁻¹⁵ A recent systematic review combining worldwide hip fracture-related mortality rates reported one-year mortality at approximately 20%.¹⁶ Another single-center study showed that patients with hip fracture who were treated nonoperatively had four times higher one-year mortality after fracture than the group that underwent surgery.¹⁷ Surgery for hip fractures is therefore considered to be an important treatment. Most reported hip fractures occur in people older than 65 years.¹⁸ The global population is aging, so the number of elderly patients with cirrhosis is reported to be increasing.¹⁹ This combination suggests the population of patients with concurrent hip fracture and cirrhosis is increasing.²⁰

Tseng et al. evaluated postoperative outcomes in 347,363 patients with hip fracture, including 2,071 with cirrhosis, from the US Nationwide Inpatient Sample. Patients with cirrhosis had higher rate of in-hospital mortality than patients without cirrhosis.²¹ Chang et al. analyzed data of 117,129 patients with hip fracture, including 4,048 with cirrhosis, from the Taiwan National Health Insurance database; they had 2–3 times higher mortality rates at three years after surgery than patients without cirrhosis.²² Elsewhere, Montomoli et al. analyzed data of 152,180 patients with hip fractures including 1,866 with cirrhosis from Danish registries; patients with cirrhosis had higher 30-day and 1-year mortality than patients without cirrhosis. Excess mortality was said to be due to complications of the fracture event rather than to preexisting comorbidity.²³

To our knowledge, however, only one study has focused on the severity of cirrhosis on the mortality related to hip fractures. Hundersmarck et al. analyzed 99 patients with hip fracture with cirrhosis stratified based on MELD scores subgroup and stratified based on compensation or decompensation status, both measures of severity of cirrhosis.²⁴ One-year mortality was 55% for MELD scores of 20–40 and 53% for patients with decompensated disease, compared with 16% for patients with MELD scores of 6–9 and 15% for patients with compensated disease. All in-hospital deaths were related to liver failure.²⁴ However, this study is limited because of the small sample sizes.

The association between severity of cirrhosis and postoperative mortality and morbidities in patients with hip fractures requires elucidation. Understanding the impact of severity of cirrhosis for patients with hip fracture on short-term outcomes is important in determination of the surgical or non-surgical management. This real-world observational study uses a nationwide inpatient database. It aims to elucidate the impact of severity of cirrhosis in patients with hip fracture regarding postoperative outcomes.

Methods:

Data source

We used diagnosis procedure combination (DPC) data from the database of the DPC Study Group funded by the Ministry of Health, Labour and Welfare (MHLW), Japan. The DPC/per-diem payment system (PDPS) is a Japanese payment system for inpatients in the acute phase of illness and provides survey data to the MHLW for the purpose of standardizing and improving the quality of medical care for hospitalized patients.²⁵ The database contains DPC data from approximately 1,200 hospitals nationwide in 2016. The DPC data consists of discharge summaries, which include the International Classification of Diseases 10th Revision (ICD-10) Codes classifying main diagnosis, the trigger diagnosis, the most and second-most medical-resource-intensive diagnoses, comorbidities, complications during hospitalization, and various disease-specific severity classifications.²⁶ The database thus includes the Child-Pugh classification for cirrhosis as well as patient details such as age, sex, body mass index (BMI), claims data of medical procedures, and daily records of drug administration.

Study population

Included in this study were patients who met all of the following criteria: (1) admitted with hip fractures (ICD-10 Codes of S72.0–S72.2) except for open-fractures (ICD-10 Codes of S72.01, S72.11, and S72.21), (2) underwent surgery for hip fractures, (3) had complete DPC files related to medical services and medications, (4) admitted and discharged between July 1, 2010 and March 31, 2021. We excluded patients if any of the variables of the Child-Pugh classification registered as 0, which was defined as cases in which classification was not possible. Patients were classified into four groups based on the Child-Pugh classification: cases without registered Child-Pugh classification, which were regarded as cases without cirrhosis in our study, and those with Child-Pugh classes A, B and C.

Variables

In this study, patients were categorized using the Child-Pugh classification. The Child-Pugh classification incorporates five variables which include the serum albumin, bilirubin, prothrombin time, ascites and encephalopathy. Each variable is scored one to three, with three indicating the most severe status. If one of the diagnoses registered to the DPC data include predefined diagnoses related to cirrhosis (ICD-10 Codes of I81, I82.0, I85.0, I85.9, I86.4, I98.2, I98.3, K71.7, K72.1, K72.9, K74.0-74.6, K76.5, and K76.6), registration of the Child-Pugh classification is mandatory. BMI was classified into six categories (< 18.5, 18.5-22.4, 22.5-24.9, 25.0-29.9, ≥ 30.0 kg/m² and missing). Elixhauser comorbidities were coded using Quan's protocol.^{27, 28}

Outcomes

The primary outcome of interest was in-hospital mortality. Secondary outcomes of interest were length of stay, postoperative length of stay, hospitalization fee, ratio of 30-day readmission and relevant postoperative complications, which included surgical-site infection (SSI), blood transfusion, acute liver failure, upper gastrointestinal bleeding (UGIB), respiratory failure, venous thromboembolism (VTE), acute coronary syndrome (ACS), heart failure (HF), acute renal failure, urinary tract infection (UTI), and sepsis (Supplementary Table 1).²⁹⁻³¹

Statistical analyses

We analyzed the database using three sets of propensity-score matching to address potential selection bias for four groups: cases without cirrhosis and cases with Child-Pugh A, B and C classifications. We compared the following three pairs: cases without cirrhosis vs Child-Pugh A classification, Child-Pugh A classification vs B classification, and Child-Pugh B classification vs C classification.

A one-to-one nearest neighbor propensity-score matched analysis without replacement procedure was performed using the MatchIt package³² in R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria).³³ We calculated three sets of propensity scores which were the likelihoods of being classified as Child-Pugh class A, B or C respectively in each pair based on three multivariable logistic regression models including patients' demographic and clinical characteristics: age, sex, six BMI categories, 30 Elixhauser comorbidities, anticoagulant use and antiplatelet use. These variables were used based on previous studies and expert opinions to predict the severity of cirrhosis.³⁴⁻³⁷

We formed three matched pairs such that the differences in propensity scores between matched cases differ by at most a fixed distance known as a caliper width. The caliper width was set as 0.2 times of standard deviation of the logit of the propensity scores, as recommended by Austin.³⁵ Balance after matching was evaluated by the absolute standardized mean difference.³⁶ An absolute standardized mean difference ≤ 0.1 was considered a negligible difference and was indicative of well-balanced matching.³⁷

We presented the risk difference (RD) and risk ratio (RR) as estimates of outcomes for each matched pair. Standard errors (SEs) of RD and RR, which were clustered robust SEs, were estimated using generalized linear models with log link functions.³⁸ All statistical analyses were performed with R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria).³³

Ethical consideration

This study was approved by the Ethics Committee, Graduate School of Medicine, Kyoto University (approval number: R0135), and was conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects of the MHLW, Japan. According to these


guidelines, the need for written informed consent was waived for this research because it did not utilize human biological specimens and all information used in the research has been anonymized.

Results:

Study population

Included in this study were 834,262 cases of patients that underwent surgery for hip fractures during the study period. Of these, we excluded cases with any one of variables of Child-Pugh classification registered as 0 (n=614). We then identified 833,648 eligible cases (Figure 1).

Figure 1. Study flow chart.



Patient characteristics and outcomes before propensity-score matching

Before matching, the cases without cirrhosis comprised 830,781 cases, patients with Child-Pugh A classification comprised 1,066 cases, patients with Child-Pugh B classification comprised 1,304 cases, and patients with Child-Pugh C classification comprised 497 cases. The characteristics and outcomes of the patients before propensity-score matching analysis are shown in Tables 1 and 2.

Our study population consisted of cases undergoing surgery, so mean ages (standard deviation) tended to be younger in more severe Child-Pugh classes. Patients with Child-Pugh A classification had a mean of 78.31 (9.92) years, those with Child-Pugh B classification had a mean of 78.31 (9.59) years, and those with Child-Pugh C classification had a mean of 76.88 (9.96) years. Ratio of patients with metastatic cancer tended to be higher in more severe Child-Pugh classes. Patients with Child-Pugh A classification had a rate of 0.75%, those with Child-Pugh B classification had a rate of 0.92%, and those with Child-Pugh C classification had a rate of 3.62%. The ratio of solid tumors without metastasis tended to be higher in more severe Child-Pugh classes. Patients with Child-Pugh A classification had a rate of 11.73%, those with Child-Pugh B classification had a rate of 14.42%, and those with Child-Pugh C classification had a rate of 20.32%. Ratio of coagulopathy including thrombocytopenia showed a tendency to be higher in more severe Child-Pugh classes. Patients with Child-Pugh A classification had a rate of 3.00%, those with Child-Pugh B classification had a rate of 4.98%, and those with Child-Pugh C classification had a rate of 5.63% (Table 1).

Table 1. Study population before propensity-score matching.

	Cases without cirrhosis	Child-Pugh class		
		A	B	C
N	830,781	1,066	1,304	497
Demographics				
age mean, SD	82.34 (10.19)	78.31 (9.92)	78.31 (9.59)	76.88 (9.96)
sex -female	645,245 (77.67%)	812 (76.17%)	948 (72.70%)	342 (68.81%)
BMI <18.5	220,518 (26.54%)	254 (23.83%)	275 (21.09%)	96 (19.32%)
18.5-22.4	336,810 (40.54%)	427 (40.06%)	507 (38.88%)	185 (37.22%)
22.5-24.9	124,259 (14.96%)	175 (16.42%)	261 (20.02%)	106 (21.33%)
25.0-29.9	74,156 (8.93%)	116 (10.88%)	155 (11.89%)	69 (13.88%)
30.0-	10,510 (1.27%)	19 (1.78%)	34 (2.61%)	15 (3.02%)
missing	64,528 (7.77%)	75 (7.04%)	72 (5.52%)	26 (5.23%)
Congestive heart failure	68,830 (8.28%)	62 (5.82%)	89 (6.83%)	34 (6.84%)
Cardiac arrhythmias	56,110 (6.75%)	43 (4.03%)	86 (6.60%)	23 (4.63%)
Valvular disease	46,983 (5.66%)	32 (3.00%)	69 (5.29%)	16 (3.22%)
Pulmonary circulation disorders	3,903 (0.47%)	4 (0.38%)	9 (0.69%)	1 (0.20%)
Peripheral vascular disorders	10,870 (1.31%)	11 (1.03%)	13 (1.00%)	0 (0.00%)
Hypertension	299,953 (36.10%)	414 (38.84%)	384 (29.45%)	88 (17.71%)
Paralysis	3,643 (0.44%)	2 (0.19%)	0 (0.00%)	1 (0.20%)
Other neurological disorders	37,253 (4.48%)	42 (3.94%)	34 (2.61%)	7 (1.41%)
Chronic pulmonary disease	33,271 (4.00%)	37 (3.47%)	41 (3.14%)	12 (2.41%)
Diabetes, uncomplicated	123,624 (14.88%)	219 (20.54%)	237 (18.17%)	93 (18.71%)
Diabetes, complicated	27,918 (3.36%)	51 (4.78%)	97 (7.44%)	26 (5.23%)
Hypothyroidism	9,697 (1.17%)	25 (2.35%)	36 (2.76%)	7 (1.41%)
Renal failure	39,016 (4.70%)	69 (6.47%)	100 (7.67%)	33 (6.64%)
Liver disease	30,427 (3.66%)	930 (87.24%)	1155 (88.57%)	435 (87.53%)
Peptic ulcer disease excluding bleeding	24,991 (3.01%)	43 (4.03%)	53 (4.06%)	17 (3.42%)
AIDS/HIV	80 (0.01%)	0 (0.00%)	0 (0.00%)	1 (0.20%)
Lymphoma	2,336 (0.28%)	5 (0.47%)	3 (0.23%)	2 (0.40%)
Metastatic cancer	4,098 (0.49%)	8 (0.75%)	12 (0.92%)	18 (3.62%)
Solid tumor without metastasis	32,282 (3.89%)	125 (11.73%)	188 (14.42%)	101 (20.32%)
Rheumatoid arthritis/collagen vascular disease	18,600 (2.24%)	46 (4.32%)	33 (2.53%)	5 (1.01%)
Coagulopathy	2,551 (0.31%)	32 (3.00%)	65 (4.98%)	28 (5.63%)
Obesity	412 (0.05%)	0 (0.00%)	3 (0.23%)	0 (0.00%)
Weight loss	778 (0.09%)	0 (0.00%)	3 (0.23%)	1 (0.20%)
Fluid and electrolyte disorders	16,580 (2.00%)	23 (2.16%)	33 (2.53%)	14 (2.82%)
Blood loss anemia	8,105 (0.98%)	11 (1.03%)	19 (1.46%)	6 (1.21%)
Deficiency anemia	31,744 (3.82%)	52 (4.88%)	81 (6.21%)	28 (5.63%)
Alcohol abuse	2,587 (0.31%)	26 (2.44%)	52 (3.99%)	28 (5.63%)
Drug abuse	35 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Psychoses	32,883 (3.96%)	20 (1.88%)	25 (1.92%)	8 (1.61%)
Depression	26,278 (3.16%)	36 (3.38%)	33 (2.53%)	7 (1.41%)
Anticoagulant use	222,278 (26.76%)	227 (21.29%)	304 (23.31%)	98 (19.72%)
Antiplatelet use	163,128 (19.64%)	121 (11.35%)	100 (7.67%)	28 (5.63%)

SD, standard deviations: BMI, body mass index: AIDS/HIV, acquired immune deficiency syndrome/human immunodeficiency virus.

Cases in more severe Child-Pugh classes of cirrhosis tended to have higher ratio of in-hospital mortality and complications. In-hospital mortality was 1.41%, 5.75% and 28.37% in Child-Pugh A classification, Child-Pugh B classification and Child-Pugh C classification, respectively. The rates of complications such as acute liver failure were 2.91%, 6.90% and 17.71% in Child-Pugh A, B and C classes, respectively (Table 2).

Table 2. Outcomes before propensity-score matching.

	Cases without cirrhosis	Child-Pugh class		
		A	B	C
N	830,781	1,066	1,304	497
Outcome				
In-hospital death	13,741 (1.65%)	15 (1.41%)	75 (5.75%)	141 (28.37%)
Length of stay mean, SD	35.90 (26.78)	39.0 (27.92)	41.9 (31.16)	52.5 (38.89)
Postoperative days mean, SD	30.92 (25.66)	33.3 (25.71)	35.8 (29.03)	45.9 (37.50)
30-day readmission	28,663 (3.45%)	59 (5.53%)	111 (8.51%)	51 (10.26%)
Hospitalization fee mean JPY, SD	1,772,150 (863,700)	1,943,972 (996,936)	2,093,716 (1,096,777)	2,528,731 (1,443,841)
Complications				
Surgical				
Surgical site infection	423 (0.05%)	2 (0.19%)	1 (0.08%)	1 (0.20%)
Blood transfusion	314,300 (37.83%)	524 (49.16%)	841 (64.49%)	393 (79.07%)
Non-surgical				
Acute liver failure	86 (0.01%)	31 (2.91%)	90 (6.90%)	88 (17.71%)
Upper gastrointestinal bleeding	24,506 (2.95%)	137 (12.85%)	153 (11.73%)	88 (17.71%)
Respiratory failure	33,831 (4.07%)	42 (3.94%)	57 (4.37%)	48 (9.66%)
Venous thromboembolism	31,761 (3.82%)	43 (4.03%)	45 (3.45%)	17 (3.42%)
Acute coronary syndrome	10,759 (1.30%)	13 (1.22%)	9 (0.69%)	3 (0.60%)
Heart failure	11,454 (1.38%)	15 (1.41%)	29 (2.22%)	7 (1.41%)
Stroke	6,076 (0.73%)	5 (0.47%)	5 (0.38%)	0 (0.00%)
Acute renal failure	1,402 (0.17%)	3 (0.28%)	7 (0.54%)	11 (2.21%)
Urinary tract infection	28,943 (3.48%)	43 (4.03%)	50 (3.83%)	20 (4.02%)
Sepsis	11,294 (1.36%)	28 (2.63%)	35 (2.68%)	34 (6.84%)

SD, standard deviations: JPY, Japanese yen.

Patient characteristics and outcomes after propensity-score matching

After propensity-score matching, the number of pairs were 1,065 (cases without cirrhosis vs Child-Pugh A classification), 1,012 (Child-Pugh class A vs B), and 489 (Child-Pugh class B vs C) (Table 3). The ratio of matched cases were 99.9%, 77.6% and 98.4% respectively. The characteristics in each pair before and after the propensity-score matching are shown in Supplementary Tables 2–4. Absolute values of standardized differences for each variable were ≤ 0.1 after propensity score matching.

The outcomes, and estimated RDs and RRs of matched cases are shown in Table 4 and Supplementary Tables 5–7. In-hospital mortality, which was the primary outcome, was 1.69% in cases without cirrhosis and 1.41% in Child-Pugh A classification (RD -0.28%; 95% CI: -1.34%–0.78%; RR 0.83; 95% CI: 0.42–1.65). In-hospital mortality was higher with statistical significance in patients with Child-Pugh B classification than those with Child-Pugh A classification (1.48% vs 5.93%; RD 4.45%; 95% CI: 2.79%–6.10%; RR 4.00; 95% CI: 2.27–7.05), and in those with Child-Pugh C classification compared with those with Child-Pugh B classification (6.34% vs 28.43%; RD 22.09%; 95% CI: 17.54%–26.63%; RR 4.48; 95% CI: 3.10–6.48) (Table 4 and Supplementary Tables 5–7).

Among the secondary outcomes, length of stay and postoperative length of stay tended to be longer, and ratio of 30-day readmission and hospitalization fee tended to be higher in cases with more severe Child-Pugh classes (Table 4 and Supplementary Tables 5–7). Regarding complications, there was no statistically significant difference in ratio of SSI, VTE, ACS, HF, stroke and UTI between groups. Meanwhile, patients with Child-Pugh C classification had higher ratio of blood transfusion, acute liver failure, UGIB, respiratory failure, acute renal failure and sepsis than those of Child-Pugh B classification (Table 4 and Supplementary Table 7). Of these, rate of acute liver failure was higher with statistical significance in the patients with Child-Pugh A classification than cases without cirrhosis (0% vs 2.91%; RD 2.91%; 95% CI: 1.90%–3.92%), in the Child-Pugh B classification than those with Child-Pugh A classification (2.87% vs 7.02%; RD 4.15%; 95% CI: 2.27%–6.03%; RR 2.45; 95% CI: 1.60–3.74), and in those with Child-Pugh C classification compared with those with Child-Pugh B classification (9.00% vs 18.00%; RD 9.00%; 95% CI: 4.71%–13.28%; RR 2.00; 95% CI: 1.42–2.82) (Table 4 and Supplementary Tables 5–7).

Table 3. Study population after propensity-score matching.

	After matching								
	Child-Pugh class			Child-Pugh class			Child-Pugh class		
	Cases without cirrhosis	A	SMD	A	B	SMD	B	C	SMD
N	1,055	1,065		1,012	1,012		489	489	
Demographics									
age -mean, SD	78.91 (10.35)	78.32 (9.91)	0.058	78.33 (9.90)	78.42 (10.20)	0.010	77.24 (9.97)	76.92 (9.97)	0.032
sex -female	831 (78.03%)	811 (76.15%)	0.045	766 (75.69%)	740 (73.12%)	0.059	395 (68.51%)	338 (69.12%)	0.013
BMI <18.5	245 (23.00%)	254 (23.85%)	0.020	242 (23.91%)	218 (21.54%)	0.057	83 (16.97%)	95 (19.43%)	0.064
18.5–22.4	433 (40.66%)	427 (40.09%)	0.011	410 (40.51%)	390 (38.54%)	0.040	190 (38.85%)	183 (37.42%)	0.029
22.5–24.9	172 (16.15%)	175 (16.43%)	0.008	167 (16.50%)	199 (19.66%)	0.082	113 (23.11%)	104 (21.27%)	0.044
25.0–29.9	115 (10.80%)	115 (10.80%)	<0.001	111 (10.97%)	114 (11.26%)	0.009	63 (12.88%)	67 (13.70%)	0.024
30.0–	24 (2.25%)	19 (1.78%)	0.033	19 (1.88%)	23 (2.27%)	0.028	14 (2.86%)	14 (2.86%)	<0.001
missing	76 (7.14%)	75 (7.04%)	0.004	63 (6.23%)	68 (6.72%)	0.020	26 (5.32%)	26 (5.32%)	<0.001
Congestive heart failure	71 (6.67%)	62 (5.82%)	0.035	58 (5.73%)	74 (7.31%)	0.064	28 (5.73%)	34 (6.95%)	0.050
Cardiac arrhythmias	47 (4.41%)	43 (4.04%)	0.019	43 (4.25%)	64 (6.32%)	0.093	21 (4.29%)	23 (4.70%)	0.020
Valvular disease	27 (2.54%)	32 (3.00%)	0.029	32 (3.16%)	42 (4.15%)	0.053	11 (2.25%)	16 (3.27%)	0.062
Pulmonary circulation disorders	3 (0.28%)	4 (0.38%)	0.016	4 (0.40%)	8 (0.79%)	0.052	1 (0.20%)	1 (0.20%)	<0.001
Peripheral vascular disorders	12 (1.13%)	11 (1.03%)	0.009	10 (0.99%)	12 (1.19%)	0.019	0 (0.00%)	0 (0.00%)	—
Hypertension	421 (39.53%)	414 (38.87%)	0.013	376 (37.15%)	363 (35.87%)	0.027	79 (16.16%)	88 (18.00%)	0.049
Paralysis	0 (0.00%)	2 (0.19%)	0.061	0 (0.00%)	0 (0.00%)	—	0 (0.00%)	0 (0.00%)	—
Other neurological disorders	36 (3.38%)	42 (3.94%)	0.030	33 (3.26%)	32 (3.16%)	0.006	6 (1.23%)	7 (1.43%)	0.018
Chronic pulmonary disease	35 (3.29%)	37 (3.47%)	0.010	34 (3.36%)	38 (3.75%)	0.021	14 (2.86%)	12 (2.45%)	0.025
Diabetes, uncomplicated	227 (21.31%)	219 (20.56%)	0.018	202 (19.96%)	205 (20.26%)	0.007	86 (17.59%)	92 (18.81%)	0.032
Diabetes, complicated	35 (3.29%)	50 (4.69%)	0.072	51 (5.04%)	66 (6.52%)	0.064	33 (6.75%)	25 (5.11%)	0.069
Hypothyroidism	23 (2.16%)	25 (2.35%)	0.013	25 (2.47%)	31 (3.06%)	0.036	7 (1.43%)	7 (1.43%)	<0.001
Renal failure	65 (6.10%)	69 (6.48%)	0.015	68 (6.72%)	80 (7.91%)	0.046	32 (6.54%)	32 (6.54%)	<0.001
Liver disease	929 (87.23%)	929 (87.23%)	<0.001	885 (87.45%)	891 (88.04%)	0.018	433 (88.55%)	429 (87.73%)	0.025
Peptic ulcer disease excluding bleeding	44 (4.13%)	43 (4.04%)	0.005	40 (3.95%)	46 (4.55%)	0.029	18 (3.68%)	17 (3.48%)	0.011
AIDS/HIV	0 (0.00%)	0 (0.00%)	—	0 (0.00%)	0 (0.00%)	—	0 (0.00%)	0 (0.00%)	—
Lymphoma	5 (0.47%)	5 (0.47%)	<0.001	3 (0.30%)	3 (0.30%)	<0.001	2 (0.41%)	2 (0.41%)	<0.001
Metastatic cancer	4 (0.38%)	8 (0.75%)	0.050	8 (0.79%)	10 (0.99%)	0.021	9 (1.84%)	12 (2.45%)	0.042
Solid tumor without metastasis	131 (12.30%)	125 (11.74%)	0.017	124 (12.25%)	133 (13.14%)	0.027	87 (17.79%)	101 (20.65%)	0.073
Rheumatoid arthritis/collagen vascular disease	45 (4.23%)	46 (4.32%)	0.005	35 (3.46%)	31 (3.06%)	0.022	3 (0.61%)	5 (1.02%)	0.045
Coagulopathy	28 (2.63%)	31 (2.91%)	0.017	32 (3.16%)	45 (4.45%)	0.067	28 (5.73%)	28 (5.73%)	<0.001
Obesity	0 (0.00%)	0 (0.00%)	—	0 (0.00%)	0 (0.00%)	—	0 (0.00%)	0 (0.00%)	—
Weight loss	0 (0.00%)	0 (0.00%)	—	0 (0.00%)	0 (0.00%)	—	1 (0.20%)	1 (0.20%)	<0.001
Fluid and electrolyte disorders	24 (2.25%)	23 (2.15%)	0.006	23 (2.27%)	31 (3.06%)	0.049	12 (2.45%)	14 (2.86%)	0.025
Blood loss anemia	7 (0.66%)	11 (1.03%)	0.041	11 (1.09%)	13 (1.28%)	0.018	4 (0.82%)	6 (1.23%)	0.041
Deficiency anemia	52 (4.88%)	52 (4.88%)	<0.001	51 (5.04%)	55 (5.43%)	0.018	26 (5.32%)	27 (5.52%)	0.009
Alcohol abuse	20 (1.88%)	26 (2.44%)	0.039	26 (2.57%)	38 (3.75%)	0.068	33 (6.75%)	27 (5.52%)	0.051
Drug abuse	0 (0.00%)	0 (0.00%)	—	0 (0.00%)	0 (0.00%)	—	0 (0.00%)	0 (0.00%)	—
Psychoses	19 (1.78%)	20 (1.88%)	0.007	18 (1.78%)	24 (2.37%)	0.042	5 (1.02%)	8 (1.64%)	0.054
Depression	46 (4.32%)	36 (3.38%)	0.049	30 (2.96%)	29 (2.87%)	0.006	9 (1.84%)	7 (1.43%)	0.032
Anticoagulant use	223 (20.94%)	227 (21.31%)	0.009	219 (21.64%)	251 (24.80%)	0.075	83 (16.97%)	97 (19.84%)	0.074
Antiplatelet use	122 (11.46%)	121 (11.36%)	0.003	97 (9.58%)	95 (9.39%)	0.007	25 (5.11%)	28 (5.73%)	0.027

SMD, standardized mean difference; SD, standard deviations; BMI, body mass index;

AIDS/HIV, acquired immune deficiency syndrome/human immunodeficiency virus.

Table 4. Outcomes after propensity-score matching.

Outcome	Child-Pugh class A vs cases without cirrhosis		Child-Pugh class B vs A		Child-Pugh class C vs B	
	RD, % (95%CI)	RR (95%CI)	RD, % (95%CI)	RR (95%CI)	RD, % (95%CI)	RR (95%CI)
Outcome						
In-hospital death	-0.28 (-1.34–0.78)	0.83 (0.42–1.65)	4.45 (2.79–6.10)	4.00 (2.27–7.05)	22.09 (17.54–26.63)	4.48 (3.10–6.48)
Length of stay mean	-0.12 (-2.56–2.33)	1.00 (0.94–1.06)	3.77 (1.09–6.45)	1.10 (1.03–1.17)	12.46 (8.41–16.52)	1.31 (1.20–1.43)
Postoperative days mean	-0.86 (-3.17–1.44)	0.97 (0.91–1.04)	3.31 (0.84–5.77)	1.10 (1.02–1.18)	11.89 (7.94–15.84)	1.35 (1.22–1.48)
30-day readmission	-1.13 (-3.14–0.89)	0.83 (0.60–1.16)	2.37 (0.18–4.56)	1.41 (1.02–1.95)	1.23 (-2.49–4.95)	1.13 (0.78–1.66)
Hospitalization fee mean JPY	83,471 (4,155–162,788)	1.04 (1.00–1.09)	164,730 (73,062–256,399)	1.08 (1.04–1.14)	451,560 (292,234–610,886)	1.22 (1.14–1.30)
Complications						
Surgical						
Surgical site infection	0.19 (-0.07–0.45)	—	-0.10 (-0.43–0.24)	0.50 (0.05–5.52)	0.00 (-0.57–0.57)	1.00 (0.06–16.03)
Blood transfusion	9.86 (5.76–13.95)	1.25 (1.14–1.37)	14.82 (10.54–19.10)	1.30 (1.20–1.41)	15.34 (9.67–21.00)	1.24 (1.14–1.35)
Non-surgical						
Acute liver failure	2.91 (1.90–3.92)	—	4.15 (2.27–6.03)	2.45 (1.60–3.74)	9.00 (4.71–13.28)	2.00 (1.42–2.82)
Upper gastrointestinal bleeding	9.95 (7.67–12.23)	4.42 (3.01–6.50)	-0.99 (-3.82–1.85)	0.92 (0.74–1.16)	6.54 (2.08–11.01)	1.60 (1.16–2.23)
Respiratory failure	1.22 (-0.31–2.75)	1.45 (0.91–2.31)	0.79 (-0.92–2.50)	1.22 (0.86–1.86)	5.11 (2.01–8.21)	2.19 (1.34–3.59)
Venous thromboembolism	0.00 (-1.63–1.63)	1.00 (0.67–1.50)	-0.59 (-2.30–1.12)	0.86 (0.55–1.34)	0.00 (-2.27–2.27)	1.00 (0.52–1.92)
Acute coronary syndrome	0.38 (-0.49–1.24)	1.44 (0.62–3.38)	-0.40 (-1.22–0.43)	0.64 (0.25–1.64)	0.00 (-0.98–0.98)	1.00 (0.20–4.96)
Heart failure	0.38 (-0.56–1.31)	1.36 (0.63–2.97)	0.69 (-0.49–1.87)	1.47 (0.76–2.83)	0.00 (-1.27–1.27)	1.00 (0.29–3.46)
Stroke	0.09 (-0.46–0.65)	1.25 (0.34–4.66)	-0.00 (-0.55–0.55)	1.00 (0.25–4.00)	—	—
Acute renal failure	0.09 (-0.32–0.51)	1.50 (0.25–8.98)	0.40 (-0.15–0.94)	3.00 (0.61–14.88)	1.64 (0.38–2.90)	9.00 (1.14–71.19)
Urinary tract infection	-0.19 (-1.88–1.50)	0.96 (0.64–1.44)	-0.00 (-1.67–1.67)	1.00 (0.64–1.56)	0.82 (-1.52–3.16)	1.25 (0.66–2.37)
Sepsis	1.41 (0.26–2.56)	2.15 (1.13–4.09)	0.30 (-1.17–1.76)	1.11 (0.66–1.87)	4.09 (1.45–6.73)	2.43 (1.34–4.41)

RD, risk difference; RR, risk ratio; CI, confidence interval; SD, standard deviations; JPY, Japanese yen. Bold indicates statistically significant.

Discussion:

We compared postoperative outcomes in patients in a nationwide inpatient database with hip fractures undergoing surgery by Child-Pugh classes representing severity of cirrhosis. Among cases with cirrhosis, cases in more severe Child-Pugh classes showed higher in-hospital mortality, longer length of overall stay and postoperative length of stay and higher hospitalization fees. Notably, significant differences were shown between Child-Pugh classes B and C. There was no statistically significant difference between the groups in ratios of SSI, VTE, ACS, HF, stroke or UTI.

Patients in more severe Child-Pugh classes of cirrhosis were associated with higher in-hospital mortality. Severity of cirrhosis was significantly associated with higher postoperative mortality in a recent retrospective cohort study where patients with hip fracture with cirrhosis were stratified based on MELD score subgroups.²⁴ In this study, all in-hospital deaths were related to liver failure.²⁴ Elsewhere, a relationship between the development and outcome of acute-on-chronic liver failure after surgical interventions.⁴² Acute complications, such as gastrointestinal bleeding, bacterial infections, development or worsening of ascites, encephalopathy, and nonobstructive jaundice, led to acute decompensation episodes.⁴³ Acute decompensation may progress further to acute-on-chronic liver failure, which is associated with high short-term mortality.⁴⁴ In the current study there were higher ratios in cases with Child-Pugh C classification of acute liver failure, UGIB, sepsis and respiratory failure including pneumonia especially compared with patients with Child-Pugh B classification. This may be related to higher in-hospital mortality as described in previous studies.^{24, 42-44}

Our results showed patients in more severe Child-Pugh classes had longer overall length of stay and postoperative length of stay and higher hospitalization fees than less severe classes. A recent retrospective cohort study reported that patients with decompensated cirrhosis undergoing orthopedic procedures had higher in-hospital mortality, longer lengths of stay and higher hospitalization costs.⁴⁵ However, there was no discussion of causes of longer length of stay and higher hospitalization cost in this study.⁴⁵ Our study nonetheless had similar findings of length of stay and hospitalization fee. This similarity may be explained by cases with more severe Child-Pugh class tending to have higher rate of complications in our study. These associations are clinically plausible, and a previous report also showed that the complications were associated with increased length of stay and hospitalization cost.⁴⁶

Our study showed no significant difference in rates of VTE, SSI or UTI, whereas cases with Child-Pugh C classification had higher rate of respiratory failure including pneumonia. A previous study analyzing patients with hip fracture with cirrhosis stratified based on MELD scores subgroups showed that the rates of postoperative complications including symptomatic thromboembolism, SSI, pneumonia and UTI were not different among MELD score of 6-19, MELD score of 10-19 and MELD score of 20-40 groups.²⁴ Our study similarly showed that the ratio of most

complications was not different between groups.

Our result showed higher ratio of respiratory failure including pneumonia in cases with Child-Pugh C classification than those with Child-Pugh B classification. A recent retrospective cohort study compared patients with and without postoperative pneumonia, and liver disease was an independent risk factors for postoperative pneumonia following surgically-treated hip fracture in geriatric patients (Odds ratio 1.61; 95% CI: 1.15–5.15).⁴⁷ Other studies reported that patients with cirrhosis had a higher incidence of postoperative pneumonia than those without.⁴⁸⁻⁵⁰ These associations are clinically plausible because infections were reported to be more frequent among the patients with cirrhosis as an effect of the immune system suppression related to the cirrhosis.^{51, 52} Altogether, our results are in line with those in these previous studies.⁴⁷⁻⁵²

Our analysis demonstrated that cases with more advanced cirrhosis had a tendency to have higher rates of blood transfusion. Patients with advanced cirrhosis were reported to have higher prevalence of coagulopathy and thrombocytopenia.⁵³ Although information on the severity of the coagulopathy and thrombocytopenia was unavailable, we adjusted coagulopathy, thrombocytopenia, anticoagulant and antiplatelet use between groups using propensity-score. Therefore, more advanced cirrhosis may have increased bleeding tendency which could not be explained by adjusted coagulopathy, thrombocytopenia, and the use of anticoagulants and antiplatelet. Cases in more severe Child-Pugh classes showed higher ratio of UGIB, and patients with advanced cirrhosis were reported to have higher rates of hemorrhage and hematomas, even after minor invasive procedures.⁵⁴ Our results with higher ratio of blood transfusion in cases with more advanced cirrhosis may be explained by increased bleeding tendency and higher ratio of UGIB and surgery by itself.

We found no statistically significant difference in rate of ACS, HF and strokes. A previous study that analyzed patients with hip fracture with cirrhosis stratified based on MELD scores subgroups only evaluated rates of postoperative complications including symptomatic thromboembolism, SSI, pneumonia and UTI.²⁴ Our propensity-matched comparison may add details on rates of postoperative complications in patients with hip fracture with cirrhosis.

Our study had several limitations. First, this was a retrospective observational study and there may have been unmeasured covariates. However, ethical issues make it impossible to conduct a randomized controlled trial for our study population. Second, we were unable to analyze the impact of cirrhosis etiology owing to data availability. Cirrhosis etiology may account for outcomes such as in-hospital mortality and acute liver failure. In a recent study, etiology did not appear to play a major role in the development of acute-on-chronic liver failure after surgery, which was associated with high short-term mortality,⁴² although it was strongly associated with acute-on-chronic liver failure in another study.⁴⁴ Third, the DPC database did not include information on factors such as surgeon and anesthesiologist volumes, and multidisciplinary collaboration system with surgeons and specialists in each hospital. A systematic review reported the surgeon volume-outcome relationship

on 15 surgical procedures and conditions.⁵⁵ Elsewhere, those who received care from high-volume anesthesiologists had a lower risk of adverse postoperative outcomes compared with those who received care from low-volume anesthesiologists.⁵⁶ Some studies reported the importance of multidisciplinary management of patients with cirrhosis.^{57,58} These factors may be associated with mortality and morbidities in our study population.

Despite several limitations, this was nonetheless a real-world observational study using a nationwide inpatient database with large sample size. Our results suggest importance of the risk stratification by severity of cirrhosis to inform on perioperative optimization and facilitate risk-benefit discussions. Patients with Child-Pugh A and B classification are known to be able to undergo most surgeries with a reasonable safety profile.⁵³ In fact, in-hospital mortality in Child-Pugh A and B classes in our study was similar to previously-reported in-hospital mortality in patients with hip fracture ranging from 1.52–11.4%.⁵⁹⁻⁶¹ On the other hand, like other surgeries, postoperative in-hospital mortality was higher in cases with higher Child-Pugh classes, notably in Child-Pugh C classification than those of Child-Pugh B classification. A recent systematic review reported a one-year mortality rate of 22% with a range from 2.4%–34.8%.¹⁶ A single center study showed that patients with hip fracture who were treated nonoperatively had four times higher one-year mortality than the operative group.¹⁷ However, our results showed cases with Child-Pugh C classification had significantly higher in-hospital mortality than those of Child-Pugh B classification. Comprehensive shared decision making may be needed for patients with Child-Pugh C classification and should include consideration of surgical risk according to the severity of cirrhosis, risk of treatment without surgery, the patient's frailty, and their personal wishes.

Conclusions:

This propensity score-matched analysis of patients with concurrent hip fracture and cirrhosis that underwent surgery demonstrated significant differences in risk of in-hospital mortality and morbidities according to severity of cirrhosis. Patients with Child-Pugh C classification may need optimization and discussions about nonsurgical management, goals of care, and overall prognosis.

References:

1. Liu Y-B, and Chen M-K. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. *World J Gastroenterol*. 2022; 28(41): 5910–5930.
2. Mokdad AA, Lopez AD, Shahrzad S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC Med*. 2014; 12: 145.
3. Northup PG, Friedman LS, and Kamath PS. AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review. *Clin Gastroenterol Hepatol*. 2019; 17(4): 595-606.
4. Simegn AE, Melesse DY, Bizuneh YB, et al. Perioperative management of patients with liver disease for non-hepatic surgery: A systematic review. *Ann Med Surg (Lond)*. 2022; 75: 103397.
5. Mahmud N, Fricker Z, Hubbard RA, et al. Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis. *Hepatology*. 2021; 73(1): 204-218.
6. Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. *Gastroenterology*. 2007; 132: 1261–1269.
7. Befeler AS, Palmer DE, Hoffman M, et al. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child–Turcotte–Pugh classification in predicting outcome. *Arch Surg*. 2005; 140: 650–654.
8. Farnsworth N, Fagan SP, Berger DH, et al. Child–Turcotte–Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. *Am J Surg*. 2004; 188: 580–583.
9. Newman KL, Johnson KM, Cornia PB, et al. Perioperative evaluation and management of patients with cirrhosis: risk assessment, surgical outcomes, and future directions. *Clin Gastroenterol Hepatol*. 2020; 18(11): 2398-2414.e3.
10. Filsoufi F, Salzberg SP, Rahmanian PB, et al. Early and late outcomes of cardiac surgery in patients with liver cirrhosis. *Liver Transpl*. 2007; 13: 990-995.
11. Koseki H, Sunagawa S, Noguchi C, et al. Incidence of and risk factors for hip fracture in Nagasaki, Japan from 2005 to 2014. *Arch Osteoporos*. 2021; 16: 111.
12. Farahmand BY, Michae IK, Ahlbom A, et al. Survival after hip fracture. *Osteoporos Int*. 2005; 16: 1583-1590.
13. Magaziner J. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. *Am J Epidemiol*. 2003; 157: 1023-1031.
14. Panula J, Pihlajamaki H, Mattila VM, et al. Mortality and cause of death in hip fracture patients aged 65 or older - a population-based study. *BMC Musculoskelet Disord*. 2011; 12: 105.
15. Peeters CMM, Visser E, Van De Ree CLP, et al. Quality of life after hip fracture in the elderly: a systematic literature review. *Injury*. 2016; 47: 1369-1382.
16. Downey C, Kelly M, Quinlan JF. Changing trends in the mortality rate at 1-year post hip

- fracture - a systematic review. *World J Orthop.* 2019; 10: 166-175.
17. Tay E. Hip fractures in the elderly: operative versus nonoperative management. *Singapore Med J.* 2016; 57(4): 178–181.
 18. Moon A, Gray A, Deehan D, et al. Neck of femur fractures in Patient's aged more than 85 years-are they a unique subset? *Geriatr Orthop Surg Rehabil.* 2011; 2: 123–127.
 19. Carrier P, Debette-Gratien M, Jacques J, et al. Cirrhotic patients and older people. *World J Hepatol.* 2019; 11(9): 663–677.
 20. Parikh ND, Chang YH, Tapper EB, et al. Outcomes of patients with cirrhosis undergoing orthopedic procedures. An analysis of the nationwide inpatient sample. *J Clin Gastroenterol.* 2019; 53: e356–e361.
 21. Tseng FJ, Gou GH, Wang SH, et al. Chronic liver disease and cirrhosis increase morbidity in geriatric patients treated surgically for hip fractures: analysis of the US Nationwide Inpatient Sample. *BMC Geriatrics.* 2022; 22: 150.
 22. Chang CH, Chang CJ, Wang YC, et al. Increased incidence, morbidity, and mortality in cirrhotic patients with hip fractures: A nationwide population-based study. *J Orthop Surg.* 2020; 28(3): 1–8.
 23. Montomoli J, Erichsen R, Gammelager H, et al. Liver disease and mortality among patients with hip fracture: a population-based cohort study. *Clin Epidemiol.* 2018; 10: 991–1000.
 24. Hundesmarck D, Groot OQ, Schuijt HJ, et al. Hip fractures in patients with liver cirrhosis: worsening liver function is associated with increased mortality. *Clin Orthop Relat Res.* 2022; 480: 1077-1088.
 25. Hayashida K, Murakami G, Matsuda, et al. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. *J Epidemiol.* 2021; 31: 1–11.
 26. Shin J-H, Kunisawa S, Imanaka Y. New outcome-specific comorbidity scores excelled in predicting in- hospital mortality and healthcare charges in administrative databases. *J Clin Epidemiol.* 2020; 126: 141–153.
 27. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD- 9-CM and ICD-10 administrative data. *Med Care.* 2005; 43: 1130-1139.
 28. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care.* 1998; 36: 8-27.
 29. Morishita T, Takada D, Shin J-H, et al. Trends, Treatment Approaches, and In-Hospital Mortality for Acute Coronary Syndrome in Japan During the Coronavirus Disease 2019 Pandemic. *J Atheroscler Thromb.* 2022; 29: 597-607.
 30. Sakamoto T, Fujiogi M, Matsui H, et al. Short-Term Outcomes of Laparoscopic and Open Total

- Gastrectomy for Gastric Cancer: A Nationwide Retrospective Cohort Analysis. *Ann Surg Oncol*. 2020; 27: 518–526.
31. Sakamoto T, Fujiogi M, Lefor AK, et al. Stent as a bridge to surgery or immediate colectomy for malignant right colonic obstruction: propensity-scored, national database study. *Br J Surg*. 2020; 107(10): 1354-1362.
 32. Daniel E. Ho, Kosuke Imai, Gary King, Elizabeth A. Stuart. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. *J Stat Softw*. 2011; 42(8): 1-28.
 33. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2022.
 34. Shin JH, Kunisawa S, Imanaka Y. New outcome-specific comorbidity scores excelled in predicting in-hospital mortality and healthcare charges in administrative databases. *J Clin Epidemiol*. 2020; 126: 141-153.
 35. Russo MW, Pierson J, Narang T, et al. Coronary Artery Stents and Antiplatelet Therapy in Patients with Cirrhosis. *J Clin Gastroenterol*. 2012; 46: 339–344.
 36. Lu DY, Saybolt MD, Kiss DH, et al. One-Year Outcomes of Percutaneous Coronary Intervention in Patients with End-Stage Liver Disease. *Clin Med Insights Cardiol*. 2020; 14: 117954682090149.
 37. Chang WH, Mueller SH, Tan YY, et al. Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding. *Lancet Reg Health Eur*. 2021; 10: 100222.
 38. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharm Stat*. 2011; 10: 150–161.
 39. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res*. 2011; 46: 399 – 424.
 40. Normand SLT, Landrum NB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. *J Clin Epidemiol*. 2001; 54: 387–398.
 41. Abadie A and Spiess J. Robust Post-Matching Inference. *J Am Stat Assoc*. 2022; 117(538): 983-995.
 42. Klein LM, Chang J, Gu W, et al. The development and outcome of acute-on-chronic liver failure after surgical intervention. *Liver Transpl*. 2020; 26: 227-237.
 43. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. *J Hepatol*. 2018; 69: 406-460.
 44. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology*. 2013; 144:

- 1426-1437.
45. Parikh ND, Chang YH, Tapper EB, et al. Outcomes of patients with cirrhosis undergoing orthopedic procedures: An analysis of the Nationwide Inpatient Sample. *J Clin Gastroenterol*. 2019; 53: e356-e361.
 46. Bail K, Goss J, Draper B, et al. The cost of hospital-acquired complications for older people with and without dementia; a retrospective cohort study. *BMC Health Serv Res*. 2015; 15: 91.
 47. Tian Y, Zhu Y, Zhang K, et al. Incidence and risk factors for postoperative pneumonia following surgically treated hip fracture in geriatric patients: a retrospective cohort study. *J Orthop Surg Res*. 2022; 17: 179.
 48. Cheng C, Wen YW, Tsai CY, et al. Impact of Child-Pugh class A liver cirrhosis on perioperative outcomes of patients with oesophageal cancer: a propensity score-matched analysis. *Eur J Cardiothorac Surg*. 2021; 59: 395-402.
 49. Valmasoni M, Pierobon ES, De Pasqual CA, et al. Esophageal cancer surgery for patients with concomitant liver cirrhosis: a single-center matched-cohort study. *Ann Surg Oncol*. 2017; 24: 763–9.
 50. Lu MS, Liu YH, Wu YC, et al. Is it safe to perform esophagectomy in esophageal cancer patients combined with liver cirrhosis? *Interact Cardiovasc Thorac Surg*. 2005; 4: 423–5.
 51. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. *Am J Gastroenterol*. 2007; 102: 1510–7.
 52. Fernandez J, Acevedo J. New antibiotic strategies in patients with cirrhosis and bacterial infection. *Expert Rev Gastroenterol Hepatol*. 2015; 9: 1495–500.
 53. Kira LN, Johnson KM, Cornia PB, et al. Perioperative Evaluation and Management of Patients with Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions. *Clin Gastroenterol Hepatol*. 2020; 18(11): 2398-2414.
 54. Ruhling V, Gunnarsson U, Dahlstrand U, et al. Wound healing following open groin hernia surgery: the impact of comorbidity. *World J Surg*. 2015; 39: 2392–2399.
 55. Morche J, Mathes T, and Pieper D. Relationship between surgeon volume and outcomes: a systematic review of systematic reviews. *Syst Rev*. 2016; 5: 204.
 56. Hallet J, Jerath A, Turgeon AF, et al. Association Between Anesthesiologist Volume and Short-term Outcomes in Complex Gastrointestinal Cancer Surgery. *JAMA Surg*. 2021; 156(5): 479-487.
 57. Bini EJ, Weinschel EH, Generoso R, et al. Impact of gastroenterology consultation on the outcomes of patients admitted to the hospital with decompensated cirrhosis. *Hepatology*. 2001; 34:1089–1095.
 58. Mellinger JL and Volk ML. Multidisciplinary Management of Patients With Cirrhosis: A Need for Care Coordination. *Clin Gastroenterol Hepatol*. 2013; 11(3): 217–223.

59. Groff H, Kheir MM, George J, et al. Causes of in-hospital mortality after hip fractures in the elderly. *Hip Int.* 2020; 30(2): 204-209.
60. Erickson BJ, Nwachukwu BU, Kiriakopoulos E, et al. In-hospital mortality risk for femoral neck fractures among patients receiving Medicare. *Orthopedics.* 2015; 38: e593– e596.
61. Sanz-Reig J, Salvador MJ, Pérez Alba JM, et al. Risk factors for in-hospital mortality following hip fracture. *Rev Espanola Cirugia Ortop Traumatol.* 2017; 61: 209–215.

Supplementary Table 1. Variables, Types of Codes, and Corresponding Codes.

Variables	Types of Codes	Codes
Surgical site infection	ICD-10	T79.3
Blood transfusion	National Insurance fee schedule code	K920
Acute liver failure	ICD-10	K70.4, K72.0, K72.1, K72.9
Upper gastrointestinal bleeding	ICD-10	I85.x, K25.x, K26.x, K27.x, K92.0, K92.1, K92.2
Respiratory failure	ICD-10	J12.x, J13.x, J14.x, J15.x, J16.x, J17.x, J18.x, J69.x, J80, J95.8, J95.9, J96.x
Venous thromboembolism	ICD-10	I26.x, I80.x, I82.x
Acute coronary syndrome	ICD-10	I20.x, I21.x, I22.x, I23.x, I24.x
Heart failure	ICD-10	I11.0, I50.x
Stroke	ICD-10	I60.x, I61.x, I62.x, I63.x, I64, I65.x, I66.x
Acute renal failure	ICD-10	N17.x, N28.8
Urinary tract infection	ICD-10	N11.0, N11.1, N13.6, N30.x, N39.0, T83.5
Sepsis	ICD-10	A02.1, A22.7, A26.7, A32.7, A39.2-4, A40.x, A41.x, A42.7, B37.7, I30.1, I33.0, O08.0, O75.3, O88.3

ICD, international classification of disease.

Supplementary Table 2. Study population before and after propensity-score matching for cases without cirrhosis and Child-Pugh class A.

	Before matching				After matching			
	Child-Pugh class		p	SMD	Child-Pugh class		p	SMD
	Cases without cirrhosis	A			Cases without cirrhosis	A		
N	830,781	1,066			1,065	1,065		
Demographics								
age mean, SD	82.34 (10.19)	78.31 (9.92)	<0.001	0.401	78.91 (10.35)	78.32 (9.91)	0.179	0.058
sex -female	645,245 (77.66%)	812 (76.17%)	0.257	0.035	831 (78.03%)	811 (76.15%)	0.327	0.045
BMI <18.5	220,518 (26.54%)	254 (23.83%)	0.049	0.063	245 (23.00%)	254 (23.85%)	0.582	0.020
18.5-22.4	336,810 (40.54%)	427 (40.06%)	0.771	0.010	433 (40.66%)	427 (40.09%)	0.825	0.011
22.5-24.9	124,259 (14.96%)	175 (16.42%)	0.196	0.040	172 (16.15%)	175 (16.43%)	0.907	0.008
25.0-29.9	74,156 (8.93%)	116 (10.88%)	0.029	0.066	115 (10.80%)	115 (10.80%)	1.000	<0.001
30.0-	10,510 (1.27%)	19 (1.78%)	0.170	0.042	24 (2.25%)	19 (1.78%)	0.538	0.033
missing	64,528 (7.77%)	75 (7.04%)	0.404	0.028	76 (7.14%)	75 (7.04%)	1.000	0.004
Congestive heart failure	68,830 (8.28%)	62 (5.82%)	0.004	0.097	71 (6.67%)	62 (5.82%)	0.474	0.035
Cardiac arrhythmias	56,110 (6.75%)	43 (4.03%)	0.001	0.121	47 (4.41%)	43 (4.04%)	0.747	0.019
Valvular disease	46,983 (5.66%)	32 (3.00%)	<0.001	0.131	27 (2.54%)	32 (3.00%)	0.597	0.029
Pulmonary circulation disorders	3,903 (0.47%)	4 (0.38%)	0.820	0.015	3 (0.28%)	4 (0.38%)	1.000	0.016
Peripheral vascular disorders	10,870 (1.31%)	11 (1.03%)	0.510	0.026	12 (1.13%)	11 (1.03%)	1.000	0.009
Hypertension	299,953 (36.10%)	414 (38.84%)	0.068	0.056	421 (39.53%)	414 (38.87%)	0.790	0.013
Paralysis	3,643 (0.44%)	2 (0.19%)	0.314	0.045	0 (0.00%)	2 (0.19%)	0.479	0.061
Other neurological disorders	37,253 (4.48%)	42 (3.94%)	0.433	0.027	36 (3.38%)	42 (3.94%)	0.564	0.030
Chronic pulmonary disease	33,271 (4.00%)	37 (3.47%)	0.418	0.028	35 (3.29%)	37 (3.47%)	0.905	0.010
Diabetes, uncomplicated	123,624 (14.88%)	219 (20.54%)	<0.001	0.149	227 (21.31%)	219 (20.56%)	0.709	0.018
Diabetes, complicated	27,918 (3.36%)	51 (4.78%)	0.013	0.072	35 (3.29%)	50 (4.69%)	0.121	0.072
Hypothyroidism	9,697 (1.17%)	25 (2.35%)	0.001	0.090	23 (2.16%)	25 (2.35%)	0.884	0.013
Renal failure	39,016 (4.70%)	69 (6.47%)	0.008	0.077	65 (6.10%)	69 (6.48%)	0.789	0.015
Liver disease	30,427 (3.66%)	930 (87.24%)	<0.001	3.087	929 (87.23%)	929 (87.23%)	1.000	<0.001
Peptic ulcer disease excluding bleeding	24,991 (3.01%)	43 (4.03%)	0.062	0.056	44 (4.13%)	43 (4.04%)	1.000	0.005
AIDS/HIV	80 (0.01%)	0 (0.00%)	1.000	0.014	0 (0.00%)	0 (0.00%)	—	—
Lymphoma	2,336 (0.28%)	5 (0.47%)	0.385	0.031	5 (0.47%)	5 (0.47%)	1.000	<0.001
Metastatic cancer	4,098 (0.49%)	8 (0.75%)	0.328	0.033	4 (0.38%)	8 (0.75%)	0.385	0.050
Solid tumor without metastasis	32,282 (3.89%)	125 (11.73%)	<0.001	0.295	131 (12.30%)	125 (11.74%)	0.739	0.017
Rheumatoid arthritis/collagen vascular disease	18,600 (2.24%)	46 (4.32%)	<0.001	0.117	45 (4.23%)	46 (4.32%)	1.000	0.005
Coagulopathy	2,551 (0.31%)	32 (3.00%)	<0.001	0.212	28 (2.63%)	31 (2.91%)	0.792	0.017
Obesity	412 (0.05%)	0 (0.00%)	0.969	0.032	0 (0.00%)	0 (0.00%)	—	—
Weight loss	778 (0.09%)	0 (0.00%)	0.618	0.043	0 (0.00%)	0 (0.00%)	—	—
Fluid and electrolyte disorders	16,580 (2.00%)	23 (2.16%)	0.789	0.011	24 (2.25%)	23 (2.16%)	1.000	0.006
Blood loss anemia	8,105 (0.98%)	11 (1.03%)	0.975	0.006	7 (0.66%)	11 (1.03%)	0.478	0.041
Deficiency anemia	31,744 (3.82%)	52 (4.88%)	0.086	0.052	52 (4.88%)	52 (4.88%)	1.000	<0.001
Alcohol abuse	2,587 (0.31%)	26 (2.44%)	<0.001	0.183	20 (1.88%)	26 (2.44%)	0.456	0.039
Drug abuse	35 (0.00%)	0 (0.00%)	1.000	0.009	0 (0.00%)	0 (0.00%)	—	—
Psychoses	32,883 (3.96%)	20 (1.88%)	0.001	0.124	19 (1.78%)	20 (1.88%)	1.000	0.007
Depression	26,278 (3.16%)	36 (3.38%)	0.755	0.012	46 (4.32%)	36 (3.38%)	0.311	0.049
Anticoagulant use	222,278 (26.76%)	227 (21.29%)	<0.001	0.128	223 (20.94%)	227 (21.31%)	0.873	0.009
Antiplatelet use	163,128 (19.64%)	121 (11.35%)	<0.001	0.230	122 (11.46%)	121 (11.36%)	1.000	0.003

SMD, standardized mean difference; SD, standard deviations; BMI, body mass index;

AIDS/HIV, acquired immune deficiency syndrome/human immunodeficiency virus.

Supplementary Table 3.

Study population before and after propensity-score matching for Child-Pugh classes A and B.

	Before matching				After matching			
	Child-Pugh class		p	SMD	Child-Pugh class		p	SMD
	A	B			A	B		
N	1,066	1,304			1,012	1,012		
Demographics								
age mean, SD	78.31 (9.92)	78.31 (9.59)	0.993	<0.001	78.33 (9.90)	78.42 (10.20)	0.825	0.010
sex -female	812 (76.17%)	948 (72.70%)	0.061	0.080	766 (75.69%)	740 (73.12%)	0.203	0.059
BMI <18.5	254 (23.83%)	275 (21.09%)	0.123	0.066	242 (23.91%)	218 (21.54%)	0.222	0.057
18.5-22.4	427 (40.06%)	507 (38.88%)	0.589	0.024	410 (40.51%)	390 (38.54%)	0.388	0.040
22.5-24.9	175 (16.42%)	261 (20.02%)	0.028	0.093	167 (16.50%)	199 (19.66%)	0.073	0.082
25.0-29.9	116 (10.88%)	155 (11.89%)	0.484	0.032	111 (10.97%)	114 (11.26%)	0.888	0.009
30.0-	19 (1.78%)	34 (2.61%)	0.226	0.056	19 (1.88%)	23 (2.27%)	0.640	0.028
missing	75 (7.04%)	72 (5.52%)	0.151	0.062	63 (6.23%)	68 (6.72%)	0.718	0.020
Congestive heart failure	62 (5.82%)	89 (6.83%)	0.360	0.041	58 (5.73%)	74 (7.31%)	0.177	0.064
Cardiac arrhythmias	43 (4.03%)	86 (6.60%)	0.008	0.114	43 (4.25%)	64 (6.32%)	0.047	0.093
Valvular disease	32 (3.00%)	69 (5.29%)	0.008	0.115	32 (3.16%)	42 (4.15%)	0.286	0.053
Pulmonary circulation disorders	4 (0.38%)	9 (0.69%)	0.451	0.043	4 (0.40%)	8 (0.79%)	0.385	0.052
Peripheral vascular disorders	11 (1.03%)	13 (1.00%)	1.000	0.003	10 (0.99%)	12 (1.19%)	0.830	0.019
Hypertension	414 (38.84%)	384 (29.45%)	<0.001	0.199	376 (37.15%)	363 (35.87%)	0.580	0.027
Paralysis	2 (0.19%)	0 (0.00%)	0.393	0.061	0 (0.00%)	0 (0.00%)	—	—
Other neurological disorders	42 (3.94%)	34 (2.61%)	0.086	0.075	33 (3.26%)	32 (3.16%)	1.000	0.006
Chronic pulmonary disease	37 (3.47%)	41 (3.14%)	0.743	0.018	34 (3.36%)	38 (3.75%)	0.719	0.021
Diabetes, uncomplicated	219 (20.54%)	237 (18.17%)	0.161	0.06	202 (19.96%)	205 (20.26%)	0.912	0.007
Diabetes, complicated	51 (4.78%)	97 (7.44%)	0.010	0.111	51 (5.04%)	66 (6.52%)	0.182	0.064
Hypothyroidism	25 (2.35%)	36 (2.76%)	0.613	0.026	25 (2.47%)	31 (3.06%)	0.498	0.036
Renal failure	69 (6.47%)	100 (7.67%)	0.296	0.047	68 (6.72%)	80 (7.91%)	0.348	0.046
Liver disease	930 (87.24%)	1155 (88.57%)	0.353	0.041	885 (87.45%)	891 (88.04%)	0.735	0.018
Peptic ulcer disease excluding bleeding	43 (4.03%)	53 (4.06%)	1.000	0.002	40 (3.95%)	46 (4.55%)	0.582	0.029
AIDS/HIV	0 (0.00%)	0 (0.00%)	—	—	0 (0.00%)	0 (0.00%)	—	—
Lymphoma	5 (0.47%)	3 (0.23%)	0.521	0.041	3 (0.30%)	3 (0.30%)	1.000	<0.001
Metastatic cancer	8 (0.75%)	12 (0.92%)	0.823	0.019	8 (0.79%)	10 (0.99%)	0.813	0.021
Solid tumor without metastasis	125 (11.73%)	188 (14.42%)	0.062	0.080	124 (12.25%)	133 (13.14%)	0.593	0.027
Rheumatoid arthritis/collagen vascular disease	46 (4.32%)	33 (2.53%)	0.022	0.098	35 (3.46%)	31 (3.06%)	0.707	0.022
Coagulopathy	32 (3.00%)	65 (4.98%)	0.020	0.101	32 (3.16%)	45 (4.45%)	0.163	0.067
Obesity	0 (0.00%)	3 (0.23%)	0.324	0.068	0 (0.00%)	0 (0.00%)	—	—
Weight loss	0 (0.00%)	3 (0.23%)	0.324	0.068	0 (0.00%)	0 (0.00%)	—	—
Fluid and electrolyte disorders	23 (2.16%)	33 (2.53%)	0.646	0.025	23 (2.27%)	31 (3.06%)	0.334	0.049
Blood loss anemia	11 (1.03%)	19 (1.46%)	0.462	0.038	11 (1.09%)	13 (1.28%)	0.837	0.018
Deficiency anemia	52 (4.88%)	81 (6.21%)	0.189	0.058	51 (5.04%)	55 (5.43%)	0.765	0.018
Alcohol abuse	26 (2.44%)	52 (3.99%)	0.047	0.088	26 (2.57%)	38 (3.75%)	0.162	0.068
Drug abuse	0 (0.00%)	0 (0.00%)	—	—	0 (0.00%)	0 (0.00%)	—	—
Psychoses	20 (1.88%)	25 (1.92%)	1.000	0.003	18 (1.78%)	24 (2.37%)	0.436	0.042
Depression	36 (3.38%)	33 (2.53%)	0.273	0.050	30 (2.96%)	29 (2.87%)	1.000	0.006
Anticoagulant use	227 (21.29%)	304 (23.31%)	0.262	0.048	219 (21.64%)	251 (24.80%)	0.103	0.075
Antiplatelet use	121 (11.35%)	100 (7.67%)	0.003	0.126	97 (9.58%)	95 (9.39%)	0.940	0.007

SMD, standardized mean difference; SD, standard deviations; BMI, body mass index;

AIDS/HIV, acquired immune deficiency syndrome/human immunodeficiency virus.

Supplementary Table 4.

Study population before and after propensity-score matching for Child-Pugh classes B and C.

	Before matching				After matching			
	Child-Pugh class		p	SMD	Child-Pugh class		p	SMD
	B	C			B	C		
N	1,304	497			489	489		
Demographics								
age mean, SD	78.31 (9.59)	76.88 (9.96)	0.005	0.145	77.24 (9.97)	76.92 (9.97)	0.621	0.032
sex -female	948 (72.70%)	342 (68.81%)	0.115	0.086	335 (68.51%)	338 (69.12%)	0.890	0.013
BMI <18.5	275 (21.09%)	96 (19.32%)	0.443	0.044	83 (16.97%)	95 (19.43%)	0.362	0.064
18.5-22.4	507 (38.88%)	185 (37.22%)	0.554	0.034	190 (38.85%)	183 (37.42%)	0.693	0.029
22.5-24.9	261 (20.02%)	106 (21.33%)	0.580	0.032	113 (23.11%)	104 (21.27%)	0.538	0.044
25.0-29.9	155 (11.89%)	69 (13.88%)	0.286	0.060	63 (12.88%)	67 (13.70%)	0.778	0.024
30.0-	34 (2.61%)	15 (3.02%)	0.751	0.025	14 (2.86%)	14 (2.86%)	1.000	<0.001
missing	72 (5.52%)	26 (5.23%)	0.899	0.013	26 (5.32%)	26 (5.32%)	1.000	<0.001
Congestive heart failure	89 (6.83%)	34 (6.84%)	1.000	0.001	28 (5.73%)	34 (6.95%)	0.512	0.050
Cardiac arrhythmias	86 (6.60%)	23 (4.63%)	0.146	0.086	21 (4.29%)	23 (4.70%)	0.877	0.020
Valvular disease	69 (5.29%)	16 (3.22%)	0.084	0.103	11 (2.25%)	16 (3.27%)	0.435	0.062
Pulmonary circulation disorders	9 (0.69%)	1 (0.20%)	0.372	0.073	1 (0.20%)	1 (0.20%)	1.000	<0.001
Peripheral vascular disorders	13 (1.00%)	0 (0.00%)	0.055	0.142	0 (0.00%)	0 (0.00%)	—	—
Hypertension	384 (29.45%)	88 (17.71%)	<0.001	0.279	79 (16.16%)	88 (18.00%)	0.497	0.049
Paralysis	0 (0.00%)	1 (0.20%)	0.616	0.064	0 (0.00%)	0 (0.00%)	—	—
Other neurological disorders	34 (2.61%)	7 (1.41%)	0.178	0.086	6 (1.23%)	7 (1.43%)	1.000	0.018
Chronic pulmonary disease	41 (3.14%)	12 (2.41%)	0.507	0.044	14 (2.86%)	12 (2.45%)	0.842	0.025
Diabetes, uncomplicated	237 (18.17%)	93 (18.71%)	0.845	0.014	86 (17.59%)	92 (18.81%)	0.679	0.032
Diabetes, complicated	97 (7.44%)	26 (5.23%)	0.120	0.091	33 (6.75%)	25 (5.11%)	0.343	0.069
Hypothyroidism	36 (2.76%)	7 (1.41%)	0.132	0.095	7 (1.43%)	7 (1.43%)	1.000	<0.001
Renal failure	100 (7.67%)	33 (6.64%)	0.519	0.040	32 (6.54%)	32 (6.54%)	1.000	<0.001
Liver disease	1155 (88.57%)	435 (87.53%)	0.592	0.032	433 (88.55%)	429 (87.73%)	0.767	0.025
Peptic ulcer disease excluding bleeding	53 (4.06%)	17 (3.42%)	0.620	0.034	18 (3.68%)	17 (3.48%)	1.000	0.011
AIDS/HIV	0 (0.00%)	1 (0.20%)	0.616	0.064	0 (0.00%)	0 (0.00%)	—	—
Lymphoma	3 (0.23%)	2 (0.40%)	0.904	0.031	2 (0.41%)	2 (0.41%)	1.000	<0.001
Metastatic cancer	12 (0.92%)	18 (3.62%)	<0.001	0.182	9 (1.84%)	12 (2.45%)	0.659	0.042
Solid tumor without metastasis	188 (14.42%)	101 (20.32%)	0.003	0.156	87 (17.79%)	101 (20.65%)	0.291	0.073
Rheumatoid arthritis/collagen vascular disease	33 (2.53%)	5 (1.01%)	0.067	0.116	3 (0.61%)	5 (1.02%)	0.723	0.045
Coagulopathy	65 (4.98%)	28 (5.63%)	0.662	0.029	28 (5.73%)	28 (5.73%)	1.000	<0.001
Obesity	3 (0.23%)	0 (0.00%)	0.672	0.068	0 (0.00%)	0 (0.00%)	—	—
Weight loss	3 (0.23%)	1 (0.20%)	1.000	0.006	1 (0.20%)	1 (0.20%)	1.000	<0.001
Fluid and electrolyte disorders	33 (2.53%)	14 (2.82%)	0.861	0.018	12 (2.45%)	14 (2.86%)	0.842	0.025
Blood loss anemia	19 (1.46%)	6 (1.21%)	0.857	0.022	4 (0.82%)	6 (1.23%)	0.751	0.041
Deficiency anemia	81 (6.21%)	28 (5.63%)	0.727	0.024	26 (5.32%)	27 (5.52%)	1.000	0.009
Alcohol abuse	52 (3.99%)	28 (5.63%)	0.165	0.077	33 (6.75%)	27 (5.52%)	0.505	0.051
Drug abuse	0 (0.00%)	0 (0.00%)	—	—	0 (0.00%)	0 (0.00%)	—	—
Psychoses	25 (1.92%)	8 (1.61%)	0.812	0.023	5 (1.02%)	8 (1.64%)	0.577	0.054
Depression	33 (2.53%)	7 (1.41%)	0.206	0.081	9 (1.84%)	7 (1.43%)	0.801	0.032
Anticoagulant use	304 (23.31%)	98 (19.72%)	0.115	0.088	83 (16.97%)	97 (19.84%)	0.283	0.074
Antiplatelet use	100 (7.67%)	28 (5.63%)	0.162	0.082	25 (5.11%)	28 (5.73%)	0.778	0.027

SMD, standardized mean difference; SD, standard deviations; BMI, body mass index;

AIDS/HIV, acquired immune deficiency syndrome/human immunodeficiency virus.

Supplementary Table 5.

Outcomes after propensity-score matching for cases without cirrhosis and Child-Pugh class A.

	Child-Pugh class		RD, % (95%CI)	P	RR (95%CI)	P
	Cases without cirrhosis	A				
N	1,065	1,065				
Outcome						
In-hospital death	18 (1.69%)	15 (1.41%)	-0.28 (-1.34-0.78)	0.602	0.83 (0.42-1.65)	0.602
Length of stay mean, SD	39.15 (29.76)	39.03 (27.93)	-0.12 (-2.56-2.33)	0.924	1.00 (0.94-1.06)	0.924
Postoperative days mean, SD	34.16 (28.76)	33.29 (25.72)	-0.86 (-3.17-1.44)	0.463	0.97 (0.91-1.04)	0.462
30-day readmission	71 (6.67%)	59 (5.54%)	-1.13 (-3.14-0.89)	0.273	0.83 (0.60-1.16)	0.274
Hospitalization fee mean JPY, SD	1,861,070 (879,277)	1,944,542 (997,230)	83,471 (4,155-162,788)	0.039	1.04 (1.00-1.09)	0.039
Complications						
Surgical						
Surgical site infection	0 (0.00%)	2 (0.19%)	0.19 (-0.07-0.45)	0.157	--	--
Blood transfusion	418 (39.25%)	523 (49.11%)	9.86 (5.76-13.95)	<0.001	1.25 (1.14-1.37)	<0.001
Non-surgical						
Acute liver failure	0 (0.00%)	31 (2.91%)	2.91 (1.90-3.92)	<0.001	--	--
Upper gastrointestinal bleeding	31 (2.91%)	137 (12.86%)	9.95 (7.67-12.23)	<0.001	4.42 (3.01-6.50)	<0.001
Respiratory failure	29 (2.72%)	42 (3.94%)	1.22 (-0.31-2.75)	0.117	1.45 (0.91-2.31)	0.120
Venous thromboembolism	43 (4.04%)	43 (4.04%)	0.00 (-1.63-1.63)	1.000	1.00 (0.67-1.50)	1.000
Acute coronary syndrome	9 (0.85%)	13 (1.22%)	0.38 (-0.49-1.24)	0.394	1.44 (0.62-3.38)	0.397
Heart failure	11 (1.03%)	15 (1.41%)	0.38 (-0.56-1.31)	0.433	1.36 (0.63-2.97)	0.435
Stroke	4 (0.38%)	5 (0.47%)	0.09 (-0.46-0.65)	0.739	1.25 (0.34-4.66)	0.740
Acute renal failure	2 (0.19%)	3 (0.28%)	0.09 (-0.32-0.51)	0.655	1.50 (0.25-8.98)	0.657
Urinary tract infection	45 (4.23%)	43 (4.04%)	-0.19 (-1.88-1.50)	0.827	0.96 (0.64-1.44)	0.827
Sepsis	13 (1.22%)	28 (2.63%)	1.41 (0.26-2.56)	0.016	2.15 (1.13-4.09)	0.019

RD, risk difference; RR, risk ratio; CI, confidence interval; SD, standard deviations; JPY, Japanese yen. Bold indicates statistically significant.

Supplementary Table 6.

Outcomes after propensity-score matching for Child-Pugh classes A and B.

	Child-Pugh class		RD, % (95%CI)	P	RR (95%CI)	P
	A	B				
N	1,012	1,012				
Outcome						
In-hospital death	15 (1.48%)	60 (5.93%)	4.45 (2.79-6.10)	<0.001	4.00 (2.27-7.05)	<0.001
Length of stay mean, SD	38.85 (28.07)	42.62 (32.33)	3.77 (1.09-6.45)	0.006	1.10 (1.03-1.17)	0.006
Postoperative days mean, SD	33.12 (25.79)	36.43 (29.84)	3.31 (0.84-5.77)	0.008	1.10 (1.02-1.18)	0.008
30-day readmission	58 (5.73%)	82 (8.10%)	2.37 (0.18-4.56)	0.034	1.41 (1.02-1.95)	0.035
Hospitalization fee mean JPY, SD	1,939,436 (1,002,526)	2,104,167 (1,115,397)	164,730 (73,062-256,399)	<0.001	1.08 (1.04-1.14)	<0.001
Complications						
Surgical						
Surgical site infection	2 (0.20%)	1 (0.10%)	-0.10 (-0.43-0.24)	0.564	0.50 (0.05-5.52)	0.572
Blood transfusion	496 (49.01%)	646 (63.83%)	14.82 (10.54-19.10)	<0.001	1.30 (1.20-1.41)	<0.001
Non-surgical						
Acute liver failure	29 (2.87%)	71 (7.02%)	4.15 (2.27-6.03)	<0.001	2.45 (1.60-3.74)	<0.001
Upper gastrointestinal bleeding	131 (12.94%)	121 (11.96%)	-0.99 (-3.82-1.85)	0.494	0.92 (0.74-1.16)	0.495
Respiratory failure	37 (3.66%)	45 (4.45%)	0.79 (-0.92-2.50)	0.365	1.22 (0.80-1.86)	0.366
Venous thromboembolism	42 (4.15%)	36 (3.56%)	-0.59 (-2.30-1.12)	0.497	0.86 (0.55-1.34)	0.498
Acute coronary syndrome	11 (1.09%)	7 (0.69%)	-0.40 (-1.22-0.43)	0.346	0.64 (0.25-1.64)	0.350
Heart failure	15 (1.48%)	22 (2.17%)	0.69 (-0.49-1.87)	0.250	1.47 (0.76-2.83)	0.253
Stroke	4 (0.40%)	4 (0.40%)	0.00 (-0.55-0.55)	1.000	1.00 (0.25-4.00)	1.000
Acute renal failure	2 (0.20%)	6 (0.59%)	0.40 (-0.15-0.94)	0.157	3.00 (0.61-14.88)	0.179
Urinary tract infection	38 (3.75%)	38 (3.75%)	0.00 (-1.67-1.67)	1.000	1.00 (0.64-1.56)	1.000
Sepsis	27 (2.67%)	30 (2.96%)	0.30 (-1.17-1.76)	0.691	1.11 (0.66-1.87)	0.691

RD, risk difference; RR, risk ratio; CI, confidence interval; SD, standard deviations; JPY, Japanese yen. Bold indicates statistically significant.

Supplementary Table 7.

Outcomes after propensity-score matching for Child-Pugh classes B and C.

	Child-Pugh class		RD, % (95%CI)	P	RR (95%CI)	P
	B	C				
N	489	489				
Outcome						
In-hospital death	31 (6.34%)	139 (28.43%)	22.09 (17.54–26.63)	<0.001	4.48 (3.10–6.48)	<0.001
Length of stay mean, SD	40.07 (26.45)	52.53 (38.51)	12.46 (8.41–16.52)	<0.001	1.31 (1.20–1.43)	<0.001
Postoperative days mean, SD	34.18 (25.47)	46.07 (37.68)	11.89 (7.94–15.84)	<0.001	1.35 (1.22–1.48)	<0.001
30-day readmission	45 (9.20%)	51 (10.43%)	1.23 (-2.49–4.95)	0.518	1.13 (0.78–1.66)	0.518
Hospitalization fee mean JPY, SD	2,078,214 (1,116,331)	2,529,774 (1,451,581)	451,560 (292,234–610,886)	<0.001	1.22 (1.14–1.30)	<0.001
Complications						
Surgical						
Surgical site infection	1 (0.20%)	1 (0.20%)	0.00 (-0.57–0.57)	1.000	1.00 (0.06–16.03)	1.000
Blood transfusion	311 (63.60%)	386 (78.94%)	15.34 (9.67–21.00)	<0.001	1.24 (1.14–1.35)	<0.001
Non-surgical						
Acute liver failure	44 (9.00%)	88 (18.00%)	9.00 (4.71–13.28)	<0.001	2.00 (1.42–2.82)	<0.001
Upper gastrointestinal bleeding	53 (10.84%)	85 (17.38%)	6.54 (2.08–11.01)	0.004	1.60 (1.16–2.23)	0.005
Respiratory failure	21 (4.29%)	46 (9.41%)	5.11 (2.01–8.21)	0.001	2.19 (1.34–3.59)	0.002
Venous thromboembolism	17 (3.48%)	17 (3.48%)	0.00 (-2.27–2.27)	1.000	1.00 (0.52–1.92)	1.000
Acute coronary syndrome	3 (0.61%)	3 (0.61%)	0.00 (-0.98–0.98)	1.000	1.00 (0.20–4.96)	1.000
Heart failure	5 (1.02%)	5 (1.02%)	0.00 (-1.27–1.27)	1.000	1.00 (0.29–3.46)	1.000
Stroke	0 (0.00%)	0 (0.00%)	—	—	—	—
Acute renal failure	1 (0.20%)	9 (1.84%)	1.64 (0.38–2.90)	0.011	9.00 (1.14–71.19)	0.037
Urinary tract infection	16 (3.27%)	20 (4.09%)	0.82 (-1.52–3.16)	0.493	1.25 (0.66–2.37)	0.494
Sepsis	14 (2.86%)	34 (6.95%)	4.09 (1.45–6.73)	0.002	2.43 (1.34–4.41)	0.004

RD, risk difference; RR, risk ratio; CI, confidence interval; SD, standard deviations; JPY, Japanese yen. Bold indicates statistically significant.